Sinovac Biotech said on Saturday that its unit’s COVID-19 vaccine has been approved for use by the general public by China’s medical products regulator
No vaccine has passed final, large-scale trials to prove it is effective and safe enough to protect people against the virus that has led to over 870,000 deaths globally.
Sinovac Biotech’s coronavirus vaccine candidate CoronaVac was approved for emergency use as part of a programme initiated in July in China to vaccinate high-risk groups such as medical staff
Its Indonesia trial comes as Southeast Asia’s most populous country grapples with spiking infection numbers, with over 127,000 cases recorded as of Tuesday